Enovis has reaffirmed its 2026 revenue guidance of US$2.31 to US$2.37 billion with 4 to 6 percent organic growth, even as it reports annual sales declines and diminishing returns on capital. The company also recorded large impairment charges and ongoing losses, raising concerns that headline growth may not translate into improved profitability. Management’s confidence in the top line contrasts with the weakening efficiency of its capital deployment, which could pressure the investment thesis that Enovis can eventually generate durable, cash-generating growth from its medtech portfolio.
Enovis CorpReaffirmed revenue guidance is overshadowed by sales declines, impairment charges, losses, and weakening returns on capital, indicating poor capital efficiency and profitability.